Want to see IN:BIOFILCHEM full AI Analyst Report?
BIOFILCHEM Stock Chart & Stats
₹31.98
₹0.75(2.34%)
At close: 4:00 PM EDT
₹31.98
₹0.75(2.34%)
Day’s Range― - ―
52-Week Range₹25.60 - ₹46.82
Previous CloseN/A
Volume6.29K
Average Volume (3M)30.43K
Market Cap
₹515.88M
Enterprise Value₹418.10
Total Cash (Recent Filing)₹33.26M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)107.7
Beta1.62
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.30
Shares Outstanding16,273,800
10 Day Avg. Volume89,231
30 Day Avg. Volume30,427
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.95
Price to Sales (P/S)1.48
P/FCF Ratio-51.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative LeverageModest leverage limits balance-sheet risk and preserves financial flexibility. Although debt increased in 2026, the overall capital structure remains relatively conservative, giving the company more capacity to absorb operating volatility than a highly indebted peer.
Growing Equity BaseA growing equity base provides a stronger funding cushion and can reduce reliance on external borrowing. This supports resilience over the medium term, particularly while profitability and cash conversion remain uneven.
Positive Net MarginThe positive net margin indicates the company remained profitable on a reported basis despite weak operating margins. If supported by recurring operations, this earnings cushion could help fund the business, though its durability requires confirmation.
Bears Say
Sharp Revenue DeclineThe steep 2026 revenue contraction reduces visibility and suggests demand or execution volatility. Persistent top-line weakness could limit operating leverage, weaken supplier and customer positioning, and make future profitability harder to sustain.
Margin CompressionMulti-year gross and EBITDA margin erosion indicates weakening pricing power, cost absorption, or product economics. Thin operating margins leave little buffer against input-cost pressure and make earnings more vulnerable to further revenue volatility.
Inconsistent Cash GenerationRepeated negative operating and free cash flow shows that reported earnings have not consistently converted into cash. This can constrain reinvestment, increase dependence on financing, and heighten balance-sheet risk if weak cash generation persists.
Biofil Chemicals & Pharmaceuticals Ltd. News
BIOFILCHEM FAQ
What was Biofil Chemicals & Pharmaceuticals Ltd.’s price range in the past 12 months?
Biofil Chemicals & Pharmaceuticals Ltd. lowest stock price was ₹25.60 and its highest was ₹46.82 in the past 12 months.
What is Biofil Chemicals & Pharmaceuticals Ltd.’s market cap?
Biofil Chemicals & Pharmaceuticals Ltd.’s market cap is ₹515.88M.
When is Biofil Chemicals & Pharmaceuticals Ltd.’s upcoming earnings report date?
Biofil Chemicals & Pharmaceuticals Ltd.’s upcoming earnings report date is Nov 12, 2026 which is in 66 days.
How were Biofil Chemicals & Pharmaceuticals Ltd.’s earnings last quarter?
Biofil Chemicals & Pharmaceuticals Ltd. released its earnings results on Aug 11, 2026. The company reported ₹0.067 earnings per share for the quarter.
Is Biofil Chemicals & Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Biofil Chemicals & Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Biofil Chemicals & Pharmaceuticals Ltd. pay dividends?
Biofil Chemicals & Pharmaceuticals Ltd. does not currently pay dividends.
What is Biofil Chemicals & Pharmaceuticals Ltd.’s EPS estimate?
Biofil Chemicals & Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biofil Chemicals & Pharmaceuticals Ltd. have?
Biofil Chemicals & Pharmaceuticals Ltd. has 16,273,800 shares outstanding.
What happened to Biofil Chemicals & Pharmaceuticals Ltd.’s price movement after its last earnings report?
Biofil Chemicals & Pharmaceuticals Ltd. reported an EPS of ₹0.067 in its last earnings report. Following the earnings report the stock price went down -1.061%.
Which hedge fund is a major shareholder of Biofil Chemicals & Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in IN:BIOFILCHEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biofil Chemicals & Pharmaceuticals Ltd.
Biofil Chemicals and Pharmaceuticals Limited, headquartered in Indore, India, is primarily involved in the country's pharmaceutical and chemical industries. This company supplies a comprehensive array of fundamental drugs and chemical compounds, including sodium chloride, potassium chloride, sodium citrate, diethyl carbamazine citrate, ferrous sulphate, dried ferrous sulphate, ferrous fumerate, micro crystalline cellulose, and dicyclomine hydrochloride. Additionally, its product line features plastic dippers and caps. Beyond its product offerings, Biofil also provides contract manufacturing services for pharmaceutical items. The company was founded in 1985.
Technical Analysis
Krebs Biochemicals & Industries Ltd.
―
Lasa Supergenerics Ltd.
―
Mangalam Drugs & Organics Ltd.
―
Par Drugs and Chemicals Limited
―
Vivimed Labs Limited
―